Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUNE-LUNG: Optimization of Immunotherapy Duration in NSCLC
NCT04880382Phase 2Terminated
- Sponsor
- Institut Bergonié
- Start
- Aug 2021
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Institut Bergonié. Primary endpoint: Assessment of the long-term benefit of PD-1 inhibition at 12 months. Started Aug 2021; status: terminated.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04880382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880382.